Cancer Cell Analysis, Instruments, Consumables and Reagents
Report Scope:
The scope of this report is broad and covers product type, end users, techniques and applications of cancer cell analysis instruments and consumables. Revenue forecasts from 2018 through 2023 are given for each of the segments and regional markets with estimated values derived from the manufacturers’ total revenues.
The report also includes a discussion of the major players across each region and explains the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors.
Report Includes:
- 100 data tables and 91 additional tables
- Detailed overview of the global market for cancer cell analysis in instruments, reagents and consumables
- Analyses of the global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Qualitative and quantitative study of the cancer cell analysis industry by product type, end user, analyses technique, application
- Assessment of the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry
- Emphasis on the vendor landscape and detailed profiles of the major vendors in the cancer cell analysis market, including Abbott Laboratories, Bio-Rad Laboratories Inc., GE Healthcare, Merck Millipore, QIAGEN Inc., Siemens Healthcare and ThermoFischer Scientific
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst’s Credentials
- BCC Custom Research
- Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market Overview
- Introduction
- Current Technologies, Trends and Advancements
- Industry Growth Drivers
- Rising Incidences of Different Types of Cancers Across the Globe
- Surging Investment for Cancer-Based Research
- Growing Importance of Cell Assay-Based Drug Development
- Increasing Demand for the Development of Personalized Medicine for Cancer
- Advancements in Stem Cell Analysis and Biomarker Technology
- Chapter 4 Market Breakdown by Technology Type
- Consumables
- Reagents
- Assay Kits
- Media
- Microplates
- Others (Beads and Blocking Sera)
- Instruments
- Cytometers
- Spectrophotometer
- Cell Counters
- Cell Isolation and Separation Instruments
- Microscopes
- Cell Microarrays
- Quantitative PCR
- Others
- Chapter 5 Market Breakdown by End User
- Pharma and Biotech Companies
- Increasing Cancer Prevalence: A Key Opportunity Provider
- Cell Therapy
- Contract Research Organizations (CROs)
- Research and Academic Institutes
- Basic Cancer Research
- Translational Research
- Clinical Research
- Clinical Trials
- Laboratories and Hospitals
- Blood Chemistry Test
- Complete Blood Count (CBC)
- Cytogenetic Analysis
- Immunophenotyping
- Sputum Cytology
- Tumor Marker Tests
- Chapter 6 Market Breakdown by Technique
- Molecular Approach
- Polymerase Chain Reaction (PCR)
- NGS (Next-Generation Sequencing)
- Microfluidics
- Others
- Cell Imaging Approach
- Fluorescent In Situ Hybridization (FISH)
- Microscopy
- High Content Screening
- Rising Adoption and Development of Anti-Cancer Drugs
- Cytometry
- Others
- Chapter 7 Market Breakdown by Application
- Cell Imaging
- Technological Advancements in Cell Imaging
- Cell Viability and Proliferation
- Cell Signaling Pathways
- RNA Expression
- Cell Growth and Manipulation
- Cell Immunotherapy
- Dendritic Cell (DC) Vaccine
- Tumor-Infiltrating Lymphocytes (TIL) Therapy
- T Cell Receptor (TCR) Therapy
- Chimeric Antigen Receptor (CAR) T cell Therapy
- Flow Cytometry
- Genotypic or Phenotypic Research
- Drug Discovery and Development
- Chapter 8 Market Breakdown by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Europe
- United Kingdom
- France
- Germany
- Spain
- Italy
- Rest of Europe
- ROW
- Latin America
- Middle East and Africa
- Chapter 9 Industry Structure of Global Cancer Cell Analysis Market
- Industry Structure and Supply Chain Analysis for Global Cancer Cell Analysis Market
- R&D
- Suppliers
- Manufacturers
- End Users
- Investment Analysis and Future Growth Prospects
- Chapter 10 Patent Analysis
- U.S. Patent Analysis
- European Patent Analysis
- Japanese Patent Analysis
- Chapter 11 Company Profiles
- ABBOTT LABORATORIES
- ACEA BIOSCIENCE INC.
- AGILENT TECHNOLOGIES INC.
- BECTON, DICKINSON AND CO.
- BIO-RAD LABORATORIES
- CELLIX LTD.
- CYNVENIO BIOSYSTEMS INC.
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE AG
- FLUIDIGM CORP.
- GE HEALTHCARE
- GENSCRIPT
- INTELLICYT CORP.
- LOGOS BIOSYSTEMS
- LONZA GROUP LTD.
- LUMACYTE LLC
- MERCK MILLIPORE
- OLYMPUS CORP.
- PERKINELMER, INC.
- PROMEGA CORP.
- QIAGEN INC.
- SIEMENS HEALTHCARE GMBH
- TECAN GROUP LTD.
- THERMOFISCHER SCIENTIFIC
- TAKARA BIO
- List of Tables
- Summary Table : Global Market for Cancer Cell Analysis, by Product Type, Through 2023
- Table 1 : Current Technologies Used in Cancer Cell Analysis
- Table 2 : Global Prevalence of Cancer, by Type, 2016
- Table 3 : Major Types of Cancer Prevalence, by Region, 2015 and 2016
- Table 4 : Investment in Cancer, by Areas of Research
- Table 5 : Investments in Cancer-Based Research
- Table 6 : Major Types of Cell-Based Assay Used in HTS for Drug Screening
- Table 7 : Products in Clinical Development and Regulatory Review, 2016
- Table 8 : Drugs in Pipeline for Selected Causes, 2017
- Table 9 : Specific Issues in Personalized Medicine and Cancer
- Table 10 : In Vivo Versus In Vitro Stem Cell Assays
- Table 11 : Biomarkers for Cancer Detection, Diagnosis and Prognosis
- Table 12 : Global Market for Cancer Cell Analysis, by Product Type, Through 2023
- Table 13 : Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
- Table 14 : A Summary of Relevant Single-cell Methods and their Applications to Cancer
- Table 15 : Global Market for Cancer Cell Analysis, by Consumables, Through 2023
- Table 16 : Global Market for Consumables in Cancer Cell Analysis, by Region, Through 2023
- Table 17 : Global Market for Reagents, by Region, Through 2023
- Table 18 : Kits and Reagents for the Separation of CSCs from Various Starting Materials
- Table 19 : Kits and Reagents for the Separation of CTCs from Various Starting Materials
- Table 20 : Global Market for Assay Kits, by Region, Through 2023
- Table 21 : Determination of Apoptosis and Necrosis in Cancer Cells
- Table 22 : Summary of Intracellular Metabolic Assays Available to Measure Cellular Proliferation
- Table 23 : Global Market for Media, by Region, Through 2023
- Table 24 : The American Cancer Society’s Estimate for Lung Cancer in the United States, 2018
- Table 25 : Global Market for Microplates, by Region, Through 2023
- Table 26 : Medicines in Development for Cancer, 2018
- Table 27 : Global Market for Other Consumables, by Region, Through 2023
- Table 28 : Global Market for Cancer Cell Analysis, by Instruments, Through 2023
- Table 29 : Global Market for Cytometers in Cancer Cell Analysis, by Type, Through 2023
- Table 30 : Global Cytometer Market, by Region, Through 2023
- Table 31 : Estimated Female Breast Cancer Deaths in the U.S., by Age, 2017
- Table 32 : Global Spectrophotometers Market, by Region, Through 2023
- Table 33 : Global Market for Cell Counters in Cancer Cell Analysis, by Type, Through 2023
- Table 34 : Automatic Cell Counter Technology
- Table 35 : Comparison Between Manual Cell Counters and Automated Cell Counters
- Table 36 : Global Market for Cell Counters, by Region, Through 2023
- Table 37 : Characteristics of Cells
- Table 38 : Cell Isolation and Separation Techniques
- Table 39 : Global Market for Cell Isolation and Separation Instruments, by Region, Through 2023
- Table 40 : Global Market for Microscopes, by Region, Through 2023
- Table 41 : Global Market for Cell Microarrays, by Region, Through 2023
- Table 42 : Global Quantitative PCR Market, by Region, Through 2023
- Table 43 : Global Market for Other Instruments, by Region, Through 2023
- Table 44 : Global Market for Cancer Cell Analysis, by End User, Through 2023
- Table 45 : Prevalence of Cancer in Major Countries, by Type, 2015
- Table 46 : Ongoing Drug Developments and Trials for Cancer
- Table 47 : Deaths, by Cancer in Major Countries, 2015
- Table 48 : Global Market for Pharma and Biotech Companies, by Region, Through 2023
- Table 49 : Technology Approvals and Advancements, by Major Players
- Table 50 : CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
- Table 51 : Development Works Initiated in CAR T Therapy
- Table 52 : Global Market for Contract Research Organizations, by Region, Through 2023
- Table 53 : Market Share of for Drugs Under Development, 2016
- Table 54 : Some of the Major Collaborations
- Table 55 : Global Market for Research Organizations and Academic Institutes, by Region, Through 2023
- Table 56 : International Cancer Research Projects, by Region, 2017-2018
- Table 57 : Clinical Trials in the Field of Cancer Research
- Table 58 : Current Grants in the U.S., by Cancer Type, 2018
- Table 59 : Investment in Cancer Research in Canada, by Cancer Type
- Table 60 : Global Market for Laboratories and Hospitals, by Region, Through 2023
- Table 61 : Share of Population with Cancer, by Type, 2016
- Table 62 : Global Market for Cancer Cell Analysis, by Technique, Through 2023
- Table 63 : Global Market for Cancer Cell Analysis Techniques, by Region, Through 2023
- Table 64 : Global Market for Molecular Approach in Cancer Cell Analysis, by Application, Through 2023
- Table 65 : Global Market for Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
- Table 66 : Global Market for PCR in Cancer Cell Analysis, by Region, Through 2023
- Table 67 : Global Cancer Incidence, by Year, 2005-2016
- Table 68 : Global Market for Next-Generation Sequencing in Cancer Cell Analysis, by Region, Through 2023
- Table 69 : NGS Sequencers and Sequencing Technology
- Table 70 : Various Enrichment Technologies for NGS
- Table 71 : Quality Control (QC) Metrics for Next-Generation Sequencing
- Table 72 : Cancer Deaths Worldwide, 2006-2016
- Table 73 : Global Market for Microfluidics in Cancer Cell Analysis, by Region, Through 2023
- Table 74 : Size-Based Cancer Cell Separation Microfluidic Devices
- Table 75 : Microfluidics Devices for Cancer Cell Biophysical Property Characterization
- Table 76 : Global Market for Other Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023
- Table 77 : Protein Arrays for the Cancer Biomarker Discovery
- Table 78 : Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Region, Through 2023
- Table 79 : Major Growth Drivers for Global Cell Imaging Approach Market
- Table 80 : Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Application, Through 2023
- Table 81 : Global Market for FISH in Cancer Cell Analysis, by Region, Through 2023
- Table 82 : Application of FISH for the Study of Different Cancer Types
- Table 83 : Global Market for Microscopy in Cancer Cell Analysis, by Region, Through 2023
- Table 84 : Clinical Trials in Microscopy
- Table 85 : Global Market for High Content Screening in Cancer Cell Analysis, by Region, Through 2023
- Table 86 : Initiatives for the Development of Anti-Cancer Drugs, 2016-2018
- Table 87 : Global Market for Cytometry in Cancer Cell Analysis, by Region, Through 2023
- Table 88 : Global Deaths Due to Leukemia, 2016
- Table 89 : Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
- Table 90 : Clinical Trials in Cytometry
- Table 91 : Global Market for Other Cell Imaging Approaches in Cancer Cell Analysis, by Region, Through 2023
- Table 92 : Global Deaths Due to Breast Cancer, 2012-2016
- Table 93 : Global Market for Cancer Cell Analysis, by Application, Through 2023
- Table 94 : Global Market for Cell Imaging Application, by Region, Through 2023
- Table 95 : Global Market for Cell Imaging in Cancer Cell Analysis, by Region, Through 2023
- Table 96 : Rising Prevalence of Cancer, by Type, 2005-2015
- Table 97 : Global Market for Cell Viability and Proliferation in Cancer Cell Analysis, by Region, Through 2023
- Table 98 : Cell Viability at Various Concentrations of Anti-Cancer Drug
- Table 99 : Global Market for Cell Signaling Pathways in Cancer Cell Analysis, by Region, Through 2023
- Table 100 : National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
- Table 101 : Global Market for RNA Expression in Cancer Cell Analysis, by Region, Through 2023
- Table 102 : Ongoing and Completed Clinical Trials on RNA Expression-based Cancer Cell Analysis
- Table 103 : Biotechnology R&D Expenditures, by Country, 2011 and 2015
- Table 104 : Key Differences in Normal Cells and Cancer Cells
- Table 105 : Global Market for Cell Growth and Manipulation in Cancer Cell Analysis, by Region, Through 2023
- Table 106 : In Vitro and In Vivo Studies Deploying Modified and Altered Exosomes for Effective Cancer Treatment
- Table 107 : Global Market for Cell Immunotherapy in Cancer Cell Analysis, by Region, Through 2023
- Table 108 : Global Market for Flow Cytometry in Cancer Cell Analysis, by Region, Through 2023
- Table 109 : Global Market for Genotypic or Phenotypic Research in Cancer Cell Analysis, by Region, Through 2023
- Table 110 : Active Clinical Studies Involving Genotypic or Phenotypic Cancer Research, 2015-2018
- Table 111 : Global Market for Drug Discovery and Development in Cancer Cell Analysis, by Region, Through 2023
- Table 112 : North American Market for Cancer Cell Analysis, by Country, Through 2023
- Table 113 : U.S. Cancer Incidence in Males, by Cancer Type, 2017
- Table 114 : U.S. Cancer Incidence in Females, by Cancer Type, 2017
- Table 115 : Current Grants, by Cancer Type, 2017
- Table 116 : Estimates of National Expenditures for Cancer Care, by Cancer Site, 2010-2017
- Table 117 : Canadian Cancer Incidence in Males, by Cancer Type, 2017
- Table 118 : Canadian Cancer Incidence in Females, by Cancer Type, 2017
- Table 119 : Current Cancer Research Funding in Canada, 2018
- Table 120 : Asia-Pacific Market for Cancer Cell Analysis, by Country, Through 2023
- Table 121 : Cancer Prevalence Based on Incidence Rates, 2016
- Table 122 : Clinical Trials for Cancer Cell Analysis
- Table 123 : Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
- Table 124 : Commonly Diagnosed Cancers in Female, by Cancer Type, 2017
- Table 125 : Percentage Change in Cancer Prevalence, 2005-2016
- Table 126 : Distribution, by Cancer Type, 2015
- Table 127 : Clinical Trials for Cancer Cell Analysis (Singapore)
- Table 128 : European Cancer Cell Analysis Market, by Country, Through 2023
- Table 129 : Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
- Table 130 : Site-specific Research Funding in the United Kingdom, 2015
- Table 131 : Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
- Table 132 : Ongoing and Completed Clinical Trials on Cancer Cell Analysis in France
- Table 133 : Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
- Table 134 : DFF-Research Projects Grants from the Danish Council for Independent Research to Promote Cancer Cell Analysis in June 2015
- Table 135 : Projects Recommended to the NCU Board for Funding, 2016
- Table 136 : ROW Cancer Cell Analysis Market, by Country, Through 2023
- Table 137 : Brazil’s New Cases of Cancer, by Gender, 2016
- Table 138 : Clinical Trials in Mexico for Cancer Cell Analysis
- Table 139 : Leading Causes of Death in Argentina and Percentage Change from 2005 to 2016
- Table 140 : Kenya’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
- Table 141 : M&A Deals in Life Science Sector, 2017
- Table 142 : Investment Analysis
- Table 143 : U.S. Cancer Cell Analysis Patent, 2018
- Table 144 : European Cancer Cell Analysis Patents, 2015-2018
- Table 145 : Japanese Cancer Cell Analysis Patent, 2015-2018
- Table 146 : Abbott: Product Portfolio
- Table 147 : Abbott: Recent Developments, 2018
- Table 148 : ACEA Biosciences Inc.: Product Portfolio
- Table 149 : ACEA Biosciences Inc.: Recent Developments, 2017 and 2018
- Table 150 : Agilent Technology Inc.: Product Portfolio
- Table 151 : Agilent Technology Inc.: Recent Developments, 2015-2017
- Table 152 : Becton, Dickinson and Co.: Product Portfolio
- Table 153 : Becton, Dickinson and Co.: Recent Developments, 2015-2018
- Table 154 : Bio-Rad Laboratories Inc.: Product Portfolio
- Table 155 : Bio-Rad Laboratories Inc.: Recent Developments, 2016 and 2017
- Table 156 : Cellix Ltd.: Product Portfolio
- Table 157 : Cynvenio Biosystems Inc.: Product Portfolio
- Table 158 : Cynvenio Biosystems Inc.: Recent Developments, 2017 and 2018
- Table 159 : Danaher Corp.: Product Portfolio
- Table 160 : Danaher Corp.: Recent Developments, 2016-2018
- Table 161 : F. Hoffmann-LA Roche AG: Product Portfolio
- Table 162 : F. Hoffmann-LA Roche AG: Recent Developments, 2015-2017
- Table 163 : Fluidigm Corp.: Product Portfolio
- Table 164 : Fluidigm Corp.: Recent Developments, 2018
- Table 165 : GE Healthcare: Product Portfolio
- Table 166 : GE Healthcare: Recent Developments, 2017 and 2018
- Table 167 : GenScript: Product Portfolio
- Table 168 : Intellicyt Corp.: Product Portfolio
- Table 169 : Intellicyt Corp.: Recent Developments, 2016-2018
- Table 170 : Logos Biosystems: Product Portfolio
- Table 171 : lonza Group Ltd.: Product Portfolio
- Table 172 : LumaCyte LLC: Product Portfolio
- Table 173 : LumaCyte LLC: Recent Developments, 2016-2018
- Table 174 : Merck Millipore: Product Portfolio
- Table 175 : Merck Millipore: Recent Developments, 2016-2018
- Table 176 : Olympus Corp.: Product Portfolio
- Table 177 : Olympus Corp.: Recent Developments, 2015-2018
- Table 178 : PerkinElmer Inc.: Product Portfolio
- Table 179 : PerkinElmer Inc.: Recent Developments, 2015-2018
- Table 180 : Promega Corp.: Product Portfolio
- Table 181 : QIAGEN Inc.: Product Portfolio
- Table 182 : QIAGEN Inc.: Recent Developments, 2015-2018
- Table 183 : Siemens Healthcare GmbH: Product Portfolio
- Table 184 : Siemens Healthcare GmbH: Recent Developments, 2016-2018
- Table 185 : Tecan Group Ltd.: Product Portfolio
- Table 186 : Tecan Group Ltd.: Recent Developments, 2015-2017
- Table 187 : ThermoFischer Scientific: Product Portfolio
- Table 188 : ThermoFischer Scientific: Recent Developments, 2017 and 2018
- Table 189 : Takara Bio: Product Portfolio
- Table 190 : Takara Bio: Recent Developments, 2017 and 2018
- List of Figures
- Summary Figure : Global Market for Cancer Cell Analysis, by Product Type, 2017-2023
- Figure 1 : Applications of Cancer Cell Analysis: A General Overview
- Figure 2 : Global Prevalence of Cancer, by Type, 2016
- Figure 3 : The Drug Discovery Process: The Assay Development Stage
- Figure 4 : Products in Clinical Development and Regulatory Review, 2016
- Figure 5 : Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023
- Figure 6 : Five Major Classes in In Vitro-Based Assays
- Figure 7 : Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018
- Figure 8 : Basic Components of a Spectrophotometer
- Figure 9 : Classification of Cell Microarrays
- Figure 10 : Key Application of Quantitative PCR or Real-Time PCR
- Figure 11 : End-User Segmentation
- Figure 12 : Workflow for Gene Expression
- Figure 13 : Prevalence of Cancer in Major Countries, by Type, 2015
- Figure 14 : Deaths, by Cancer in Major Countries, 2015
- Figure 15 : CAR T Cell Therapy in Immuno-Oncology Medicine Development, 2017
- Figure 16 : CAR T Cell Therapy Mechanism
- Figure 17 : Private Risk Sharing Contracts Announced, 1990-2017
- Figure 18 : Market Share for the Drugs Under Development, 2016
- Figure 19 : Projects in Development Based on Novel Approaches, by Type, 2016
- Figure 20 : Primary Growth Drivers
- Figure 21 : Application of Single-Cell Analysis in Cancer Research
- Figure 22 : Prevalence of Prostate Cancer in the United States
- Figure 23 : Share of Population with Cancer, by Type, 2016
- Figure 24 : Workflow for Laboratories Undertaking Molecular Pathology for Cancer Patients from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Samples
- Figure 25 : Clinical Use of Molecular Diagnostics
- Figure 26 : Global Cancer Incidence, by Year, 2005-2016
- Figure 27 : Cancer Deaths Worldwide, 2006-2016
- Figure 28 : Subsegments of Cell Imaging Approach
- Figure 29 : Advantages Offered by Fluorescent In Situ Hybridization
- Figure 30 : Types of Microscopy Techniques
- Figure 31 : Advantages Offered by High Content Screening
- Figure 32 : Global Deaths Due to Leukemia, 2016
- Figure 33 : Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018
- Figure 34 : Global Deaths Due to Breast Cancer, 2012-2016
- Figure 35 : Applications of Cancer Cell Analysis
- Figure 36 : Types of Cancer Cell Imaging
- Figure 37 : Workflow for an Imaging-Based Cell Migration Experiment
- Figure 38 : Cell Viability at Various Concentrations of Anti-Cancer Drug
- Figure 39 : Mechanism of Cell Signaling
- Figure 40 : Types of Cell Signaling Pathways
- Figure 41 : National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016
- Figure 42 : Techniques of RNA Expression
- Figure 43 : Biotechnology R&D Expenditures, by Country, 2011 and 2015
- Figure 44 : Antitumor Impacts of Innate Immune Cells
- Figure 45 : Integration of Gene Therapy and Stem Cells for Cancer Treatment
- Figure 46 : Production Process of CAR T Cells
- Figure 47 : Flow Cytometry Automated Cancer Cell Analysis Pipeline
- Figure 48 : Application of Single-Cell Sequencing Technology in Tumor Evolution and Metastasis
- Figure 49 : Major Breakthroughs in Cancer Research in India
- Figure 50 : Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
- Figure 51 : Commonly Diagnosed Cancers in Females, by Cancer Type, 2017
- Figure 52 : Distribution, by Cancer Type, 2015
- Figure 53 : Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
- Figure 54 : Workflow of Anticancer Drug Discovery
- Figure 55 : Site-specific Research Funding in the United Kingdom, 2015
- Figure 56 : Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
- Figure 57 : Estimates of Spain’s Cancer Incidence in Men and Women, by Cancer Type, 2015
- Figure 58 : Keyna’s Prevalence of Cancer, by Cancer Type, 2015 and 2016
- Figure 59 : Industry Process Flow within Cancer Cell Analysis Market
- Figure 60 : Outline of Cancer Cell Analysis Industry
- Figure 61 : R&D Phase from Conceptualization to Development
- Figure 62 : Marketing Matrix for Cancer Cell Analysis Products
- Figure 63 : Factors Influencing Contracts with Suppliers within the Cancer Cell Analysis Market
- Figure 64 : Factors Driving M&A Deals Across the Life Science Sector
- Figure 65 : Generalized Manufacturing Process Flow for Cancer Cell Analysis Products
- Figure 66 : Global Oncology Therapeutic and Care Spending, 2013-2020